This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About

About

Efficacy
MOAMist MomentsSafety & Dosing

Safety &
Dosing

SafetyDosing & AdministrationFormulary CoverageSavings & Support

Savings
& Support

Savings & Support OptionsPrior Authorization ResourcesMaterialsVideo
Prescribing InformationPatient Information Instructions for UseIndication Press Release
Formulary Coverage Lookup ToolCoverage continues to expand for ZAVZPRET nationwide
Find ZAVZPRET specific formulary coverage in your area
*Some plans may not display due to health plan-specific policy. The information provided is not a guarantee of coverage or payment (partial or full) and is subject to change without notice.
*Some plans may not display due to health plan-specific policy. The information provided is not a guarantee of coverage or payment (partial or full) and is subject to change without notice.

‡Majority of plans require prior authorization.
While Pfizer strives to make this information as timely and accurate as possible, it makes no claims, promises or guarantees about the accuracy, completeness, or adequacy of the contents, and expressly disclaims liability for errors and omissions in the contents. Pfizer does not guarantee coverage of insured benefits; all benefits are subject to the insured's plan requirements. Please consult the health plan directly for comprehensive policy information. Reference in this information to any specific payor plan does not constitute endorsement, recommendation or favoring by Pfizer and inclusion in a medical policy does not imply comparable or superior efficacy/safety of drug products.
Sources: Managed Markets Insight & Technology, LLC, database as of October, 2024. IQVIA database as of November, 2024.
†Eligible commercially insured patients can, for one time only, access ZAVZPRET at no cost while benefits are being verified for one prescription fill, with a combined maximum of 6 devices total. Insurance coverage must be approved by the payor for patients to continue receiving ZAVZPRET with no out-of-pocket cost. No membership fees. Only available for commercially insured patients. This is not health insurance. The full terms and conditions can be accessed at zavzpret.com/copay-terms.

†Eligible commercially insured patients can, for one time only, access ZAVZPRET at no cost while benefits are being verified for as many as two prescription fills, with a combined maximum of 12 devices total. Insurance coverage must be approved by the payor for patients to continue receiving ZAVZPRET with no out-of-pocket cost. No membership fees. Only available for commercially insured patients. This is not health insurance. The full terms and conditions can be accessed at zavzpret.com/copay-terms.

 Savings for eligible patients

Patients may be able to save with the ZAVZPRET copay card.†

 Get savings info Loading Connect with a sales representative to learn more
Request a representative
Loading

†Eligible commercially insured patients can, for one time only, access ZAVZPRET at no cost while benefits are being verified for one prescription fill, with a combined maximum of 6 devices total. Insurance coverage must be approved by the payor for patients to continue receiving ZAVZPRET with no out-of-pocket cost. No membership fees. Only available for commercially insured patients. This is not health insurance. The full terms and conditions can be accessed at zavzpret.com/copay-terms.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-ZAZ-USA-0878
You are now leaving PfizerPro

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367

INDICATION

ZAVZPRET® (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Important Safety InformationContraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, facial swelling, and urticaria, have occurred in patients treated with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists.

If signs or symptoms of Raynaud’s phenomenon develop, discontinue ZAVZPRET. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms. 

Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs <1%).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.
 
Use in Specific Populations: Pregnancy: It is not known if ZAVZPRET can harm an unborn baby. Lactation: It is not known whether ZAVZPRET passes into breast milk. Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.
IndicationZAVZPRET (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Please click here for full
Prescribing Information.